Tango Therapeutics Q4 net loss widens

Tango Therapeutics

05/03/2026 12:11

Overview

Biotechnology firm reported Q4 net loss of $38.7 mln vs $30.8 mln loss a year ago; no collaboration revenue

Company holds $343 mln cash, funding operations into 2028

Company advancing vopimetostat trials in pancreatic cancer, enters new collaborations

Outlook

Tango plans to start a pivotal study for vopimetostat in pancreatic cancer in 2026

Initial data from vopimetostat + RAS(ON) inhibitors study expected in 2026

Tango's cash runway extends into 2028, supporting clinical initiatives

Result Drivers

VOPIMETOSTAT TRIALS - Strong enrollment in vopimetostat + RAS(ON) inhibitors combination study, showing early safety and efficacy

NEW SUPPLY AGREEMENT - Tango entered a supply agreement with Erasca to evaluate vopimetostat with ERAS-0015 in clinical trials

ROBUST CASH POSITION - Company holds $343 mln cash, funding operations into 2028

Company press release: ID:nGNXbpqw7v

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.29
Q4 Net Income
-$38.75 mln
Q4 Basic EPS
-$0.29
Q4 Operating Expenses
$41.86 mln
Q4 Operating Income
-$41.86 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tango Therapeutics Inc is $14.00, about 13.4% above its March 4 closing price of $12.35

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)